Re Contract

RNS Number:4908N
Celsis International PLC
14 July 2003



                      Celsis International plc



Celsis International plc announces preferred supplier agreement with
                           GlaxoSmithKline





Celsis International plc, a world leading rapid microbial testing company whose
diagnostic systems detect and measure contamination for the pharmaceutical,
personal care, dairy and beverage industries, announces it has agreed a
preferred supplier contract with GlaxoSmithKline for rapid microbial testing
systems.  Celsis have already implemented six systems in GlaxoSmithKline sites.



The Celsis rapid testing system provides product screening results in as little
as 24 hours, enabling potential microbial quality problems to be detected sooner
as well as reducing product release times compared to other more traditional
screening methods.  The net result to Celsis customers is significant financial
savings through reduced inventory and warehousing costs.



Jay LeCoque, Chief Executive of Celsis stated:



"We are delighted to have secured this agreement with GlaxoSmithKline, a major
global pharmaceutical company, and believe it highlights two things: 1) the
increasing global acceptance of Celsis technology among the major pharmaceutical
companies demonstrating that our years of regulatory partnerships are starting
to show returns, and 2) the continued progress Celsis is making with the Global
Corporate Account Management (GCAM) programme in implementing Celsis technology
not just in the UK or the US, but anywhere our customers have a manufacturing or
R&D facility in the world."



                                                                    14 July 2003


Enquiries:

Celsis International plc                               Tel: [phone]
Jay LeCoque, Chief Executive Officer
Jenny Parsons, Corporate Communications
College Hill                                           Tel: [phone]
Nicholas Nelson



Notes to editors



Celsis International plc

Celsis International plc is a world leader in the development and supply of
rapid diagnostic and monitoring systems to detect and measure microbial
contamination in finished products bound for consumers.  It has successfully
developed tests for use in the pharmaceutical, cosmetic and toiletries, food and
beverage industries and is associated with some of the best-known high street
brands in these consumer areas.



These tests are based upon the years of research in enzyme technology that
employ numerous methods for the rapid detection of microbial contamination.  The
result is that microbial testing times are reduced from around five days to a
little over one day, thus lending significant cost advantages to Celsis'
customers.



Celsis International plc also has a leading cGMP laboratory services, supporting
the R&D and manufacturing based testing needs of the pharmaceutical,
biotechnology and personal care industries.  This business unit currently
operates primarily in the United States.



For more information on Celsis International plc go to www.celsis.com


                      This information is provided by RNS
            The company news service from the London Stock Exchange
END

CNTUAABROORBAAR